PMV Pharmaceuticals
PMVP
86 hedge funds and large institutions have $1.44B invested in PMV Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 43 increasing their positions, 15 reducing their positions, and 11 closing their positions.
187% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 15
45% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 11
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
10% more capital invested
Capital invested by funds: $1.31B → $1.44B (+$131M)
6% more funds holding
Funds holding: 81 → 86 (+5)
4.7% more ownership
Funds ownership: 89.14% → 93.84% (+4.7%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$35.2M |
| 2 |
JP Morgan Chase
New York
|
+$23.6M |
| 3 |
BlackRock
New York
|
+$16.4M |
| 4 |
DM
Deerfield Management
New York
|
+$12.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$17.9M |
| 2 |
IVM
InterWest Venture Management
San Francisco,
California
|
-$16.7M |
| 3 |
PCS
Personal CFO Solutions
Chester,
New Jersey
|
-$15.7M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$9.89M |
| 5 |
EC
Euclidean Capital
New York
|
-$9.04M |
PMVP Hedge Fund Activity: Q2 2021 in Review
86 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q2 2021, worth a combined $1.44B — up 9.9% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new PMVP positions and 11 closed out — a net gain of 5 holders — while 43 added to existing stakes and 15 trimmed.
The largest buyer was Vanguard Group, adding an estimated $35.2M. The largest seller was Avoro Capital Advisors, cutting an estimated $17.9M.
- 86 institutional investors held PMV Pharmaceuticals (PMVP) as of Q2 2021, up from 81 in Q1 2021.
- Funds reported $1.44B of PMV Pharmaceuticals stock for Q2 2021, up 9.9% quarter-over-quarter.
- 16 funds opened new PMV Pharmaceuticals positions in Q2 2021 and 11 closed out, a net change of +5 holders.
- The largest PMV Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $35.2M added.
- The largest PMV Pharmaceuticals seller in Q2 2021 was Avoro Capital Advisors, an estimated $17.9M sold.
Based on aggregated 13F filings for Q2 2021.